Literature DB >> 7679168

Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity.

K R Wyse1, V Ye, T J Campbell.   

Abstract

Plasma drug concentrations in patients who develop torsade de pointes while receiving quinidine or disopyramide treatment have been reported to be usually in or below the therapeutic range, whereas patients developing the same complication during sotalol treatment usually have drug concentrations well above the therapeutic range. We wished to provide a cellular electrophysiologic rationale for this observation. Standard intracellular microelectrode techniques were used to record action potentials (APs) from canine Purkinje fibers at interstimulus intervals (ISI) of 1,000-6,000 ms, with and without three varying concentrations of quinidine, disopyramide, and sotalol. Cesium chloride 0.5 mM was added to reduce spontaneous diastolic depolarization. We observed a biphasic response in action potential duration (APD) to quinidine and disopyramide. Low concentrations tended to prolong APD, particularly at slower drive rates, whereas this effect tended to reverse as the concentration was increased. In contrast, sotalol produced a consistent, monophasic dose-dependent increase in APD across the therapeutic concentration range and well beyond it. We also observed an apparent increased likelihood of early afterdepolarizations (EADs), with or without triggered activity, at low concentrations of quinidine and disopyramide, with a trend toward reversal as the concentration was increased. We conclude that the biphasic dose response observed for APD with quinidine and disopyramide is due to the opposing effects of these agents on outward potassium and inward sodium currents and may cast some light on the clinical observation noted above. Sotalol on the other hand appears to produce EADs and triggered activity only at high concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679168     DOI: 10.1097/00005344-199302000-00019

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  Field and action potential recordings in heart slices: correlation with established in vitro and in vivo models.

Authors:  Herbert M Himmel; Alexandra Bussek; Michael Hoffmann; Rolf Beckmann; Horst Lohmann; Matthias Schmidt; Erich Wettwer
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

4.  Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guinea-pig ventricular cells.

Authors:  I Kodama; R Suzuki; K Maruyama; J Toyama
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

5.  Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans.

Authors:  H Furushima; S Niwano; M Chinushi; K Ohhira; A Abe; Y Aizawa
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

6.  The effect of amiodarone pretreatment on survival of mice with cocaine toxicity.

Authors:  Christopher R DeWitt; Nathan Cleveland; Richard C Dart; Kennon Heard
Journal:  J Med Toxicol       Date:  2005-12

7.  Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle.

Authors:  D K Martin; Y Nakaya; K R Wyse; T J Campbell
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

Review 8.  Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review.

Authors:  Eleftherios M Kallergis; Christos A Goudis; Emmanuel N Simantirakis; George E Kochiadakis; Panos E Vardas
Journal:  ScientificWorldJournal       Date:  2012-04-19

Review 9.  Drug-induced cardiac arrhythmias: incidence, prevention and management.

Authors:  J C Doig
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.228

10.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.

Authors:  Arnon Adler; Dana Fourey; Adaya Weissler-Snir; Waseem Hindieh; Raymond H Chan; Michael H Gollob; Harry Rakowski
Journal:  J Am Heart Assoc       Date:  2017-05-26       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.